TERT and cancer: As such, larger cohorts may be needed to increase sensitivity/significance, and the selected hTERT promotor region could be extended to the TERT hyper-methylated oncological region (THOR), a 433-bp genomic region encompassing 52 CpG sites located immediately upstream of the TERT core promotor, associated with cancer-specific upregulation of TERT expression (Lee et al., 2019).